Medical Health & Life Science Research News

Latest report on the Global cancer molecular biomarkers market - size, share, segment analysis and industry forecast to 2020

Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids.

- Advertisement -
- Membership expired -

Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular biomarkers market can be segmented into immunoassays, immunohistochemical (IHC) tests, genetic and genomic markers, proteomics, flow cytometry, stem cell markers, monoclonal antibodies, pharmacogenomics, DNA microarrays, and IVD multivariate index assays (IVDMIA).

On the basis of discovery , the cancer molecular biomarkers market can be segmented into genetic methods, protein methods, and imaging. Genetic methods include DNA arrays, southern blot, polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH), and reverse transcriptase polymerase chain reaction (RT-PCR).

- Advertisement -
- Membership expired -
Protein methods include immunohistochemistry (IHC) and mass spectrometry (MS). Imaging methods include positron emission tomography (PET), computed tomography (CT), magnetic resonance spectroscopy (MRS), x-ray, ultrasound, magnetic resonance imaging (MRI), and biophotonics.

North America has the largest market  for cancer molecular biomarkers due to the growing IT industry, technological advancements, rise in the incidences of cancer, growing spending from government  and private  healthcare organizations, and improved healthcare infrastructure in this region.The North America market for cancer molecular biomarkers is followed by Europe. Asia is expected to witness high growth rate in thecancer molecular biomarkers market in  the next few years due toincreasing research and development activities, rise in government  intervention, growing awareness regarding cancer molecular biomarkers, and improving healthcare infrastructurein the region.

http://www.persistencemarketresearch.com/market-research/cancer-molecular-biomarkers-market.asp Make an Inquiry about this news

Factors such as technological advancements, increasing research and development activities, increase in funding from various government and non-government organizations, rise in healthcare  expenditure, non invasive technology, increasing incidences of cancer, and streamlined drug delivery process are expected to drive the market for cancer molecular biomarkers .In addition, growing survival rates and increased accuracy of diagnosis with the help of biomarkers are expected to drive market for cancer molecular biomarkers. However, issues  related to reimbursement, high cost of diagnosis, requirement of immediate processing , lack  of awareness, and various validation issues aresome of the major factors restraining growth of the globalcancer molecular biomarkers market.

Growing populationand economies  in developing countries such as India and China is expected to drive growth of thecancer molecular biomarkers market in Asia. In addition,despite high cost involved in R&D, pharmaceutical companies are showing increased interest in this field and innovations along with technological advancement such as emergence of genetic based in vitro diagnostics, enhanced therapeutic effectiveness and decrease in the severity of the adverse effects are expected to offer new opportunities for global cancer molecular biomarkers market .

Increasing number of mergers and acquisitions, risingnumber of collaborations, and product launches are some of the latest trends in the global cancer molecular biomarkers market.Some of the major companies operating in the global cancer molecular biomarkers market are Correlogic Systems, Inc., AgendiaBv, bioMerieux S.A, Aureon Laboratories, Inc., Astellas Pharma US, Inc., and Becton. In addition, other companies operating in the global cancer molecular biomarkers market include Diadexus, Inc., Abbott Laboratories, Affymetrix, Inc., Clarient, Inc., Biomoda, Inc., Beckman Coulter, Inc., and Dickinson and Company.

Request Full TOC: http://www.persistencemarketresearch.com/toc/3841 Make an Inquiry about this news

Key points covered in the report

  • The Report segments the market on the basis of types, application, products, technology, etc (as applicable)
  • The report covers geographic segmentation

    • North America
    • Europe
    • Asia
    • RoW
  • The report presents the market size and forecast for the different segments and geographies for the period of 2010 to 2020
  • It profiles some of the leading companies operating in the market
  • The report includes Porter’s five forces analysis of the market

For more information:

Make an Inquiry about this report HERE! Make an Inquiry about this news
  • www.persistencemarketresearch.com
  • www.persistencemarketresearch.com/market-research/cancer-mol…
  • www.persistencemarketresearch.com/forthcoming-reports.asp
  • persistencemarketresearchblog.wordpress.com
  • www.persistencemarketresearch.com/toc/3841
  • twitter.com/addiethomes
  • persistencemarketresearchblog.wordpress.com

News From

Persistence Market ResearchPersistence Market Research
Category: Market Research Publishers and RetailersCompany profile: Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intel ...